Antibody synergy
By Brian Finrow and Jim Roberts We just released a paper on the preclinical development of LMN-201, Lumen’s orally delivered cocktail of therapeutic proteins for preventing C. difficile infection. In the news release we also shared that LMN-201 met its primary...
Lumen reversed logo Science Pipeline News About Careers Contact News Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection
– Preclinical data demonstrate LMN-201’s potential for preventing disease in at-risk patients — Lumen also announces successful Cohort 1 results in Phase 1 clinical trial Seattle, WA, December 23, 2021 – Lumen Bioscience, a clinical-stage biopharmaceutical...
Democratizing Biologics With Lumen Biosciences Brian Finrow, J.D. and Craig Behnke, Ph.D
Listen Now
Development of an intranasal/oral spirulina-based PfCSP malaria vaccine
Click hereRecent Post
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases